Tempest Therapeutics Bolsa (NASDAQ: TPST)

Tempest Therapeutics

TEMPEST THERAPEUTICS INC

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics Inc

Earnings

Press Releases

Tempest Reports Year End 2024 Financial Results and  Provides Business Update

Health Care

General

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

News

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Opinion

After Major Oncology Conference, All Eyes Turn to Industry Innovation

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

CTOR

CTXR

ONCY

TPST

TSX:ONC

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Celularity

Equillium

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Generation Bio

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

Medicus Pharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

RenovoRx

Skye Bioscience

Senti Biosciences

Xilio Therapeutics

Scotiabank

HC Wainwright & Co.

Piper Sandler

Jefferies

Ladenburg Thalmann

Screenshot 2025-09-08 at 3.59.27 PM

Biotech

BDRX

RXRX

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled

BDRX-logo

PVLA

How Biodexa Is Racing To Get Its Phase 3 Program In FAP Under Way And Gain First-Mover Advantage In A $7B Addressable Market

Comments

Tempest Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL